FINWIRES · TerminalLIVE
FINWIRES

Ecolab Pick of the Week at Smart Insider Following Director Share Purchase

By

Ecolab (ECL) was Smart Insider's stock pick of the week after Director Eric Green bought $1 million in shares at $276.64 apiece on Sept. 11.

Green, who joined the board in December 2022, doubled his holdings through his first acquisition at the company after recently stepping down as chair and chief executive of West Pharmaceutical, Smart Insider said in a Tuesday note.

Ecolab was previously assigned a +N rating in June following share purchases by Lead Independent Director David MacLennan, Director Michel Doukeris, and Executive Vice President Benjamin Clark, according to the firm.

The insider activity is significant given that the transactions occurred while the stock was trading near multi-year highs rather than under market pressure, it added.

Smart Insider upgraded Ecolab from +N to +1, indicating a strong positive signal.

Price: $272.31, Change: $+2.35, Percent Change: +0.87%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA